WO2023161668 - COMPOSITIONS AND METHODS FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
National phase entry:
Publication Number
WO/2023/161668
Publication Date
31.08.2023
International Application No.
PCT/IB2022/000089
International Filing Date
28.02.2022
Title **
[English]
COMPOSITIONS AND METHODS FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
[French]
COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE LA FIBROSE PULMONAIRE IDIOPATHIQUE
Applicants **
NUFORMIX TECHNOLOGIES LIMITED
6th Floor, 60 Gracechurch Street
London EC3V 0HR, GB
Inventors
HOLLAND, Joanne
20B Pages Close, Histon
Cambridge, Cambridgeshire, CB24 9HF, GB
BORTHWICK, Lee
The University of Newcastle Upon Tyne
King's Gate, Newcastle upon Tyne NE1 7RU, GB
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1429 | |
| EPO | Filing, Examination | 7874 | |
| Japan | Filing | 589 | |
| South Korea | Filing | 482 | |
| USA | Filing, Examination | 6910 |
Total: 17284 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The treatment of idiopathic pulmonary fibrosis (IPF) using a therapeutically effective amount of a combination of tranilast and pirfenidone, or a therapeutically effective amount of a combination of tranilast and nintedanib, is described. Tranilast may be administered as an adjunctive therapy to the treatment of IPF by either pirfenidone or nintedanib. The combination of tranilast and pirfenidone and the combination of tranilast and nintedanib may also be synergistically effective to treat IPF. Methods and pharmaceutical compositions for treating idiopathic pulmonary fibrosis (IPF) are also described.[French]
L'invention concerne le traitement de la fibrose pulmonaire idiopathique (IPF) à l'aide d'une quantité thérapeutiquement efficace d'une combinaison de tranilast et de pirfénidone, ou d'une quantité thérapeutiquement efficace d'une combinaison de tranilast et de nintedanib. Le tranilast peut être administré en tant que thérapie d'appoint au traitement de l'IPF par la pirfénidone ou le nintedanib. La combinaison de tranilast et de pirfénidone et la combinaison de tranilast et de nintedanib peuvent également être efficaces de manière synergique pour traiter l'IPF. L'invention concerne également des méthodes et des compositions pharmaceutiques pour le traitement de la fibrose pulmonaire idiopathique (IPF).